Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - Lexaria Bioscience Corp. has announced a definitive agreement for a registered direct offering of 2,661,600 shares of common stock at a price of $1.315 per share, along with a concurrent private placement of unregistered warrants to purchase the same number of shares at an exercise price of $1.19 per share [1][2]. Group 1: Offering Details - The total gross proceeds from the offering are expected to be approximately $3.5 million before deducting fees and expenses [2]. - The offering is being conducted under a "shelf" registration statement that was declared effective by the SEC on January 30, 2025 [3]. - The warrants will be immediately exercisable and will expire five years from the effectiveness of the resale registration statement [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to advance research and development efforts, fund working capital, and cover other general corporate purposes [2]. Group 3: Company Background - Lexaria Bioscience Corp. specializes in drug delivery platforms, particularly its patented DehydraTECH™ technology, which enhances the absorption of drugs through oral delivery [6][7]. - The company holds a robust intellectual property portfolio with 56 patents granted and additional patents pending worldwide [7].